Calamos Wealth Management LLC Has $3.59 Million Stock Holdings in McKesson Corporation (NYSE:MCK)

Calamos Wealth Management LLC increased its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 14.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,335 shares of the company's stock after buying an additional 658 shares during the quarter. Calamos Wealth Management LLC's holdings in McKesson were worth $3,590,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. CVA Family Office LLC increased its holdings in shares of McKesson by 6.0% in the 1st quarter. CVA Family Office LLC now owns 265 shares of the company's stock worth $178,000 after acquiring an additional 15 shares during the period. Palisade Asset Management LLC grew its position in McKesson by 2.1% in the 1st quarter. Palisade Asset Management LLC now owns 715 shares of the company's stock worth $481,000 after purchasing an additional 15 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of McKesson by 0.6% in the first quarter. Parallel Advisors LLC now owns 2,501 shares of the company's stock valued at $1,683,000 after purchasing an additional 16 shares during the period. Frank Rimerman Advisors LLC raised its holdings in shares of McKesson by 2.2% during the fourth quarter. Frank Rimerman Advisors LLC now owns 807 shares of the company's stock valued at $460,000 after buying an additional 17 shares during the last quarter. Finally, Eagle Rock Investment Company LLC boosted its position in shares of McKesson by 0.4% during the first quarter. Eagle Rock Investment Company LLC now owns 4,798 shares of the company's stock worth $3,229,000 after buying an additional 17 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Up 2.2%

McKesson stock traded up $16.11 during mid-day trading on Monday, hitting $735.41. The company's stock had a trading volume of 999,234 shares, compared to its average volume of 927,042. The stock has a market capitalization of $92.01 billion, a P/E ratio of 28.47, a P/E/G ratio of 1.44 and a beta of 0.48. McKesson Corporation has a twelve month low of $464.42 and a twelve month high of $736.96. The stock's fifty day moving average price is $714.17 and its two-hundred day moving average price is $658.30.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, topping the consensus estimate of $9.83 by $0.29. McKesson had a negative return on equity of 201.12% and a net margin of 0.92%. The business had revenue of $90.82 billion during the quarter, compared to analyst estimates of $94 billion. During the same period last year, the company posted $6.18 EPS. The company's revenue was up 18.9% compared to the same quarter last year. Equities analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 1st. Stockholders of record on Monday, June 2nd were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, June 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.39%. McKesson's dividend payout ratio is currently 10.99%.

Analyst Ratings Changes

MCK has been the topic of several recent analyst reports. Cfra Research downgraded McKesson from a "moderate buy" rating to a "hold" rating in a research note on Friday, April 4th. Wall Street Zen upgraded shares of McKesson from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Bank of America increased their target price on shares of McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a research report on Friday, May 9th. UBS Group raised their target price on shares of McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Finally, Morgan Stanley upped their price target on shares of McKesson from $745.00 to $770.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $696.42.

Insider Buying and Selling at McKesson

In other news, CFO Britt J. Vitalone sold 1,878 shares of the firm's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $717.91, for a total value of $1,348,234.98. Following the completion of the sale, the chief financial officer owned 14,028 shares of the company's stock, valued at $10,070,841.48. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Brian S. Tyler sold 19,370 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $705.93, for a total value of $13,673,864.10. Following the transaction, the chief executive officer directly owned 51,243 shares in the company, valued at $36,173,970.99. The trade was a 27.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,117 shares of company stock valued at $23,526,451 over the last three months. 0.08% of the stock is owned by insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.